El informe
Noticias verificadas sobre financiación, sedes y liderazgo de las empresas más innovadoras del mundo
20 informes y contando
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints
Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.
SpyGlass Pharma Opens New Headquarters in Irvine
SpyGlass Pharma opened a 33,000-square-foot headquarters in Irvine, California, on August 27, 2026, moving from its former facility in Aliso Viejo as it prepares for its first product launch.
Collegium Pharmaceutical Plans Headquarters Move to Downtown Boston
Collegium Pharmaceutical plans to move its corporate headquarters from Stoughton to One Lincoln in downtown Boston during the first quarter of 2027.
Idorsia Appoints Roland Wandeler Chief Executive Officer
Idorsia appointed Grifols Biopharma president Roland Wandeler CEO, succeeding ad-interim CEO Jean-Paul Clozel, to lead the company’s next phase of growth.
Resilience Relocates Corporate Headquarters to Blue Ash, Ohio
Biomanufacturing company Resilience is relocating its corporate headquarters from San Diego to a major packaging and supply operation in Blue Ash.
Apnimed Appoints Kevin R. Lind Chief Executive Officer
Apnimed appointed Board Chair Kevin R. Lind as CEO, succeeding founder Lawrence G. Miller, who will become Vice Chair, as the company builds capabilities toward a potential commercialization of AD109.
Umoja Biopharma Raises $100M in Series C
Umoja Biopharma, a HealthTech company based in Seattle, WA, has raised $100M in Series C at a $800M valuation led by DCVC Bio, Double Point Ventures.
Vor Biopharma Raises $110M in Series C
Vor Biopharma, a Biotech company based in 200 Sidney Street, Cambridge, MA 02139, has raised $110M in Series C at a $700M valuation led by 5AM Ventures, Fidelity, SR One, Novartis Venture Fund, Cormorant Asset Management.
Mostrando 9 informes • Página 1 • Categoría: all
Mantente a la vanguardia del mercado
Recibe insights semanales en tu bandeja de entrada. Sin spam, solo inteligencia.